Discontinuation of dolutegravir, elvitegravir/cobicistat and raltegravir because of toxicity in a prospective cohortJosep M. Llibre, Juan Tiraboschi, Adrián Curran et al.|HIV Medicine|2019Cited by 38
Real world effectiveness of standard of care triple therapy versus two-drug combinations for treatment of people living with HIVRamón Teira, Juan Berenguer, Helena Díaz-Cuervo et al.|PLoS ONE|2021Cited by 10
Multiomics plasma effects of switching from triple antiretroviral regimens to dolutegravir plus lamivudineElisa de Lazzari, Estebán Martínez, Eugenia B Negredo et al.|Journal of Antimicrobial Chemotherapy|2024Cited by 6